Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction

K. Takenaka, S. Yasuda, S. Miyazaki, T. Kurita, Y. Sutani, I. Morii, S. Daikoku, S. Kamakura, H. Nonogi

研究成果: Article査読

28 被引用数 (Scopus)

抄録

Nifekalant hydrocholoride, a novel class III antiarrhythmic agent, was used as the treatment in 4 patients with extensive anterior infarction and severe ventricular dysfunction. The malignant ventricular tachyarrhythmia was effectively suppressed at a relatively low dose, without compromising the hemodynamics, indicating that this potent K+ channel blocker has therapeutic potential for acute myocardial infarction.

本文言語English
ページ(範囲)60-62
ページ数3
ジャーナルJAPANESE CIRCULATION JOURNAL
65
1
DOI
出版ステータスPublished - 2001
外部発表はい

ASJC Scopus subject areas

  • 生理学
  • 循環器および心血管医学

フィンガープリント

「Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル